Clinical Trials
32
Trial Phases
4 Phases
Drug Approvals
43
Drug Approvals
Perindopril tert-Butylamine
- Product Name
- 培哚普利叔丁胺盐
- Approval Number
- H20160493
- Approval Date
- Aug 30, 2016
Perindopril tert-Butylamine
- Product Name
- 培哚普利叔丁胺盐
- Approval Number
- H20160492
- Approval Date
- Aug 30, 2016
Clinical Trials
Distribution across different clinical trial phases (28 trials with phase data)• Click on a phase to view related trials
To Evaluate Safety, Tolerability and Pharmacokinetics of GRC 27864 in Healthy Subjects and Elderly Healthy Subjects
- First Posted Date
- 2015-02-11
- Last Posted Date
- 2015-12-15
- Lead Sponsor
- Glenmark Pharmaceuticals S.A.
- Target Recruit Count
- 32
- Registration Number
- NCT02361034
- Locations
- 🇬🇧
Covance Clinical Research Unit Ltd, Leeds, Yorkshire, United Kingdom
News
Alphamab Oncology Receives IND Approval for First-in-Class Bispecific ADC JSKN022 Targeting PD-L1 and Integrin αvβ6
Alphamab Oncology's IND application for JSKN022, a novel bispecific antibody-drug conjugate targeting both PD-L1 and integrin αvβ6, has been officially accepted by China's NMPA.
UK Court of Appeal Grants AstraZeneca Interim Injunction Against Glenmark's Generic Dapagliflozin
The UK Court of Appeal reversed a lower court decision, awarding AstraZeneca an interim injunction against Glenmark's generic dapagliflozin for type II diabetes until the validity hearing judgment.
UK Court of Appeal Grants AstraZeneca Injunction Against Glenmark's Diabetes Generic
The UK Court of Appeal has blocked Glenmark Pharmaceuticals from launching its generic version of dapagliflozin until the conclusion of ongoing patent validity proceedings, overturning a previous High Court decision.